F. J. Martinez (Ann Arbor, United States of America), C. Albera (Turin, Italy)
Interstitial lung diseases, mortality and associated risk factors
M. C. De Salvo, J. A. Gonzalez, D. R. Rey, A. M. Miranda (Buenos Aires, Argentina)
|  |
Correlation of a progression of fibrotic changes in idiopathic pulmonary fibrosis 1 year after a diagnosis with initial functional and immunologic parameters
M. Vasakova, I. Hricikova, A. Edrisova, V. Bartu (Prosecnice, Czech Republic)
| |
Time-course changes in pulmonary haemodynamics in patients with idiopathic pulmonary fibrosis (IPF) waiting for lung transplantation (LT)
G. Jebrak, O. Brugieres, G. Dauriat, H. Mal, G. Leseche, M. Fournier (Paris, France)
| |
IFIGENIA-study in IPF: effects of N-acetylcysteine (NAC) on CRP, dyspnea, exercise test and HRCT
M. Demedts, J. Behr, R. Buhl, U. Costabel, H. M. Jansen, M. Thomeer, B. Wallaert, I. Lankhorst, M. Sardina, G. Corvasce, M. Montanari, F. Laurent, J. Verschakelen, C. D. R. Flower (Leuven, Belgium)
| |
IFIGENIA: effects of N-acetylcysteine (NAC) on primary end points VC and DLco
M. Demedts, J. Behr, R. Buhl, G. Corvasce, U. Costabel, P. N. R. Dekhuijzen, H. M. Jansen, I. Lankhorst, N. Kormoss, W. MacNee, M. Montanari, S. Petruzzelli, M. Sardina, M. Thomeer, B. Wallaert (Leuven, Belgium)
| |
IFIGENIA (idiopathic pulmonary fibrosis international group exploring NAC I annual): effects of N-acetylcysteine (NAC) on lung function and gas exchange in IPF pati
J. Behr, M. Demedts, R. Buhl, G. Corvasce, U. Costabel, R. Dekhuijzen, H. Jansen, I. Lankhorst, N. Kormoss, M. Sardina, M. Thomeer, B. Wallaert (Munich, Germany)
| |
Interstitial lung disease in patients with connective tissue diseases - a report of 3 cases
M. L. T. Due, S. V. Navarra (Quezon City, The Philippines)
| |
Exhaled carbon monoxide in sarcoidosis
G. Ciarleglio, V. A. M. Martino, M. Pieroni, M. Refini, P. Rottoli, P. Sestini (Siena, Italy)
| |
Clinical benefits of ambroxol and millimeter wave therapy combination in sarcoidosis
H. L. Baradzina, N. V. Ponachevnaya, I. L. Kotovich, A. V. Tahanovich (Minsk, Belarus)
| |
The evaluatuion of effectiveness of small doses of pentoxifylline in combination with tocopherol acetate in intrathoracic sarcoidosis
A. A. Vizel, E. A. Vizel, G. R. Nasretdinova, M. E. Gouryleva (Kazan, Russia)
| |
Sarcoidosis associated with hashimoto thyroiditis, type 1 diabetes mellitus and psoriasis
N. Kalac, E. T. Putun, S. E. Uluhan, L. Y. Aydin, S. Kaya, Y. Agackiran (Ankara, Turkey)
| |
Bronchial reactivity for histamine and serum angiotensin converting enzyme (sACE) activity in sarcoidosis patients
M. Martusewicz-Boros, E. Puscinska, P. Boros, S. Wesolowski, D. Gorecka, K. Roszkowski-Sliz (Warsaw, Poland)
| |
Familial pulmonary alveolar microlithiasis(Report of two siblings)
O. Okutan, Z. Kartaloglu, A. Ilvan, E. Bozkanat, E. Demirer, E. Silit, S. Yildirim, Y. Narin (Istanbul, Turkey)
| |
Clinical characteristics of pulmonary alveolar microlithiasis in Japan
T. Tachibana, T. Johkoh, H. Sumikawa, S. Abe, S. Nakajima, T. Ishida (Osaka, Sapporo, Nara, Kurasiki, Japan)
| |
Pulmonary alveolar microlithiasis: case report
C. E. Dagli, C. Tanrikulu, F. Gurkan, R. Isik (Diyarbakir, Turkey)
| |
Pulmonary alveolar proteinosis and GMSCF antibodies: a case series
H. Bell, K. Nakata, E. Gabbay, Q. Summers, F. Lake (Perth, Australia; Tokyo, Japan)
| |
Whole lung lavage (WLL) for patients with pulmonary alveolar proteinosis
A. A. Bazhanov, I. V. Dvorakovskaia, O. P. Baranova, A. T. Ivanov (St Petersburg, Russia)
| |
Successful treatment by GMCSF of pulmonary alveolar proteinosis relapsing after a first GMCSF course
S. Boniface, F. Milhe, J. Y. Gaubert, M. Badier, B. Chetaille, M. Reynaud-Gaubert, A. Magnan (Marseilles, France)
| |
Alveolar proteinosis: epidemiology, possibilities of diagnosis
M. Bratkovskis, I. Gorina (Riga, Latvia)
| |